MX338731B - Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados. - Google Patents
Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados.Info
- Publication number
- MX338731B MX338731B MX2013003678A MX2013003678A MX338731B MX 338731 B MX338731 B MX 338731B MX 2013003678 A MX2013003678 A MX 2013003678A MX 2013003678 A MX2013003678 A MX 2013003678A MX 338731 B MX338731 B MX 338731B
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- monooxygenase
- cytochrome
- inhibitor
- intermediates involved
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/70—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16649809P | 2009-04-03 | 2009-04-03 | |
| PCT/US2010/029633 WO2010115000A2 (en) | 2009-04-03 | 2010-04-01 | Methods and intermediates for preparing pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX338731B true MX338731B (es) | 2016-04-28 |
Family
ID=42634770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010397A MX2011010397A (es) | 2009-04-03 | 2010-04-01 | Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados. |
| MX2013003678A MX338731B (es) | 2009-04-03 | 2010-04-01 | Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010397A MX2011010397A (es) | 2009-04-03 | 2010-04-01 | Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados. |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8497396B2 (enExample) |
| EP (2) | EP3009434A1 (enExample) |
| JP (8) | JP5612662B2 (enExample) |
| KR (3) | KR101728375B1 (enExample) |
| CN (4) | CN111217808A (enExample) |
| AP (1) | AP2887A (enExample) |
| AR (1) | AR076027A1 (enExample) |
| AU (1) | AU2010232559B2 (enExample) |
| BR (1) | BRPI1012638B8 (enExample) |
| CA (4) | CA3008903C (enExample) |
| CL (1) | CL2011002370A1 (enExample) |
| CO (1) | CO6400216A2 (enExample) |
| EA (2) | EA201590979A1 (enExample) |
| EC (1) | ECSP11011391A (enExample) |
| ES (1) | ES2548252T3 (enExample) |
| HK (1) | HK1223912A1 (enExample) |
| IL (4) | IL215399A (enExample) |
| MX (2) | MX2011010397A (enExample) |
| NZ (4) | NZ617773A (enExample) |
| PE (1) | PE20120617A1 (enExample) |
| PT (1) | PT2414325E (enExample) |
| SG (2) | SG10201404926UA (enExample) |
| TW (2) | TW201518283A (enExample) |
| UA (1) | UA108738C2 (enExample) |
| UY (1) | UY32535A (enExample) |
| WO (1) | WO2010115000A2 (enExample) |
| ZA (1) | ZA201107430B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| JP2012140390A (ja) * | 2011-01-06 | 2012-07-26 | Sumitomo Chemical Co Ltd | α−アミノ−γ−ブチロラクトンの製造方法 |
| CA2836768A1 (en) * | 2011-05-02 | 2012-11-08 | Gilead Sciences, Inc. | Amorphous solid salts |
| SG11201404527QA (en) * | 2012-02-03 | 2014-08-28 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
| WO2014047849A1 (zh) * | 2012-09-27 | 2014-04-03 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
| WO2014105777A1 (en) * | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
| CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
| US20170035911A1 (en) * | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
| EP3077373B1 (en) | 2013-12-03 | 2018-09-12 | Mylan Laboratories Ltd. | Preparation of cobicistat intermediates |
| CN104193643B (zh) * | 2014-09-12 | 2016-02-10 | 宁波九胜创新医药科技有限公司 | 用于合成抗艾滋病药物增强剂cobicistat的中间体 |
| CN104447472A (zh) * | 2014-11-06 | 2015-03-25 | 江苏森萱医药化工股份有限公司 | D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法 |
| CN104557565B (zh) * | 2015-01-08 | 2016-07-06 | 浙江工业大学 | 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法 |
| US10454867B2 (en) * | 2015-02-09 | 2019-10-22 | Airwatch Llc | Enhanced e-mail delivery to mobile devices |
| WO2016132378A2 (en) * | 2015-02-18 | 2016-08-25 | Msn Laboratories Private Limited | Novel process for the preparation of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2- [(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl] methyl} carbamoyl) amino] -4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate |
| CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
| US20180085387A1 (en) | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
| CN109232301B (zh) * | 2018-10-15 | 2021-01-01 | 天津希恩思生化科技有限公司 | 一种四异丙基肼的制备方法 |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110878071A (zh) * | 2019-11-21 | 2020-03-13 | 华南农业大学 | 一种α-氨基-γ-丁内酯及其盐的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2324549T5 (es) * | 1999-06-04 | 2012-10-31 | Abbott Laboratories | Solución farmacéutica que comprende ritonavir, un disolvente (ácido graso de cadena larga) y agua |
| US20030153771A1 (en) | 2001-09-27 | 2003-08-14 | Kolb Hartmuth C. | Large scale synthesis of optically pure aziridines |
| WO2003106445A1 (en) * | 2002-06-12 | 2003-12-24 | Qsi Pharma A/S | Compounds and methods for controlling bacterial virulence |
| JP2008507611A (ja) * | 2004-07-23 | 2008-03-13 | ザ プロクター アンド ギャンブル カンパニー | 油及びデンプン汚れに対する低温での洗浄力を向上させる液体洗剤組成物 |
| US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| AP2985A (en) * | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| LT2487163T (lt) * | 2007-02-23 | 2016-10-25 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| CA2692331A1 (en) * | 2007-07-06 | 2009-01-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| ES2555209T3 (es) * | 2008-01-04 | 2015-12-29 | Gilead Sciences, Inc. | Inhibidores del citocromo P450 |
| BRPI0911871A8 (pt) | 2008-05-02 | 2018-03-06 | Gilead Sciences Inc | uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico |
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки |
-
2010
- 2010-01-04 UA UAA201111540A patent/UA108738C2/ru unknown
- 2010-03-31 AR ARP100101077 patent/AR076027A1/es unknown
- 2010-03-31 TW TW103133537A patent/TW201518283A/zh unknown
- 2010-03-31 TW TW99109929A patent/TWI464165B/zh active
- 2010-04-01 KR KR1020117026120A patent/KR101728375B1/ko active Active
- 2010-04-01 CA CA3008903A patent/CA3008903C/en active Active
- 2010-04-01 CA CA2754698A patent/CA2754698C/en active Active
- 2010-04-01 JP JP2012503704A patent/JP5612662B2/ja active Active
- 2010-04-01 CN CN202010112624.8A patent/CN111217808A/zh active Pending
- 2010-04-01 PT PT107130759T patent/PT2414325E/pt unknown
- 2010-04-01 NZ NZ617773A patent/NZ617773A/en unknown
- 2010-04-01 EP EP15171216.3A patent/EP3009434A1/en not_active Withdrawn
- 2010-04-01 PE PE2011001737A patent/PE20120617A1/es active IP Right Grant
- 2010-04-01 CN CN201080014307.7A patent/CN102438982B/zh active Active
- 2010-04-01 CA CA2925137A patent/CA2925137C/en active Active
- 2010-04-01 US US12/752,639 patent/US8497396B2/en active Active
- 2010-04-01 NZ NZ726536A patent/NZ726536A/en unknown
- 2010-04-01 NZ NZ59486410A patent/NZ594864A/en unknown
- 2010-04-01 NZ NZ708978A patent/NZ708978A/en unknown
- 2010-04-01 KR KR1020177009970A patent/KR101874557B1/ko active Active
- 2010-04-01 BR BRPI1012638A patent/BRPI1012638B8/pt active IP Right Grant
- 2010-04-01 EA EA201590979A patent/EA201590979A1/ru unknown
- 2010-04-01 AP AP2011005864A patent/AP2887A/xx active
- 2010-04-01 EP EP10713075.9A patent/EP2414325B1/en active Active
- 2010-04-01 SG SG10201404926UA patent/SG10201404926UA/en unknown
- 2010-04-01 WO PCT/US2010/029633 patent/WO2010115000A2/en not_active Ceased
- 2010-04-01 KR KR1020187018487A patent/KR20180077324A/ko not_active Ceased
- 2010-04-01 SG SG2011069937A patent/SG174585A1/en unknown
- 2010-04-01 AU AU2010232559A patent/AU2010232559B2/en active Active
- 2010-04-01 CN CN201710518109.8A patent/CN107382997B/zh active Active
- 2010-04-01 CA CA3083433A patent/CA3083433C/en active Active
- 2010-04-01 MX MX2011010397A patent/MX2011010397A/es active IP Right Grant
- 2010-04-01 EA EA201190179A patent/EA022739B1/ru unknown
- 2010-04-01 CN CN201510160505.9A patent/CN104876888B/zh active Active
- 2010-04-01 MX MX2013003678A patent/MX338731B/es unknown
- 2010-04-01 ES ES10713075.9T patent/ES2548252T3/es active Active
- 2010-04-05 UY UY32535A patent/UY32535A/es not_active Application Discontinuation
-
2011
- 2011-09-06 CO CO11114749A patent/CO6400216A2/es not_active Application Discontinuation
- 2011-09-26 CL CL2011002370A patent/CL2011002370A1/es unknown
- 2011-09-27 IL IL215399A patent/IL215399A/en active IP Right Grant
- 2011-10-11 ZA ZA2011/07430A patent/ZA201107430B/en unknown
- 2011-10-12 EC ECSP11011391 patent/ECSP11011391A/es unknown
-
2013
- 2013-06-24 US US13/925,302 patent/US8853210B2/en active Active
-
2014
- 2014-05-20 JP JP2014104007A patent/JP5986599B2/ja active Active
- 2014-09-03 US US14/476,622 patent/US9115100B2/en active Active
-
2015
- 2015-03-10 IL IL237643A patent/IL237643A/en active IP Right Grant
- 2015-03-10 IL IL237642A patent/IL237642A/en active IP Right Grant
- 2015-07-14 US US14/799,090 patent/US9428473B2/en active Active
-
2016
- 2016-01-28 JP JP2016014135A patent/JP6180561B2/ja active Active
- 2016-09-09 HK HK16110713.7A patent/HK1223912A1/en unknown
-
2017
- 2017-01-11 IL IL250068A patent/IL250068A0/en unknown
- 2017-02-27 JP JP2017034914A patent/JP6336161B2/ja active Active
- 2017-07-28 JP JP2017146329A patent/JP6491706B2/ja active Active
-
2018
- 2018-06-18 JP JP2018115527A patent/JP2018162274A/ja not_active Withdrawn
-
2020
- 2020-08-07 JP JP2020134426A patent/JP2020189861A/ja not_active Withdrawn
-
2022
- 2022-10-19 JP JP2022167506A patent/JP2023002679A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX338731B (es) | Metodo para preparar un inhibidor de monooxigenasa del citocromo p450, e intermediarios involucrados. | |
| UA104438C2 (uk) | Спосіб одержання дабігатрану і його проміжних сполук | |
| PH12012500954A1 (en) | Method for producing dabigatran etexilate | |
| SG148142A1 (en) | Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof | |
| EP2357260A4 (en) | Case hardening steel, carburized component, and method for producing case hardening steel | |
| MY169734A (en) | Methods for improving pharmacokinetics | |
| MX2009008660A (es) | Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos. | |
| TN2013000354A1 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
| EA201070538A1 (ru) | Улучшенный способ получения сложных диэфиров | |
| EP4021619A4 (en) | CARBON SEQUESTRATION PROCESS | |
| WO2012074855A3 (en) | Methods of identifying a cellular nascent rna transcript | |
| TW200825088A (en) | Processes for preparing intermediates of pemetrexed | |
| GEP20156234B (en) | Agomelatine intermediates and preparation method thereof | |
| MX357509B (es) | Sintesis de cleistantina a y derivados de la misma. | |
| EP3792634A3 (en) | Method of assaying 5-fu | |
| MX2009001150A (es) | Aditivo que contiene titanio. | |
| MX2013009388A (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
| EP2257160A4 (en) | DIAMIDE OF CYTOCHROM P450 | |
| WO2011000516A3 (en) | Gamma globin therapy | |
| MX344429B (es) | Nuevos compuestos de hexahidropirroloimidazolona. | |
| WO2012161438A3 (ko) | 음원 서비스를 제공하는 방법, 모바일 단말기 및 기록매체 | |
| IN2012DN00346A (enExample) | ||
| TW200728267A (en) | Processes and intermediates for the preparation of prostaglandins | |
| MX2009014191A (es) | Procedimiento para la preparacion de derivados de dioxazina. | |
| IN2013MN01107A (enExample) |